interferon gamma-1b + antifungals

This is a combination therapy consisting of interferon gamma-1b, a recombinant human cytokine, and antifungal agents (such as amphotericin B or fluconazole). Interferon gamma-1b acts as an immunomodulator by binding to the interferon-gamma receptor on immune cells, activating the JAK/STAT signaling pathway. This leads to enhanced activation of macrophages and natural killer (NK) cells, boosting the host's innate immune response against infections. Antifungals in this combination directly target fungal pathogens through various mechanisms depending on the specific agent used (e.g., disrupting cell membrane integrity for amphotericin B or inhibiting ergosterol synthesis for azoles). The combination has been studied primarily as adjunctive therapy in severe fungal infections such as cryptococcal meningitis and invasive aspergillosis, particularly in immunocompromised patients. Clinical studies suggest that adding interferon gamma-1b to standard antifungal regimens may improve mycologic clearance rates and clinical outcomes compared to antifungals alone[1][2][3].

Other names

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary AspergillosisIFN-gamma + antifungals